secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001655759-25-000136
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q2 2025: NDA for vepdegestrant; CEO to retire; cash $861M
-----------------------------------------------------------------

- Submitted NDA to FDA for vepdegestrant in ESR1m ER+/HER2- advanced breast cancer.
- VERITAC-2 Phase 3: 2.9-month PFS improvement in ESR1m subgroup; ITT not significant.
- Cash $861.2M at June 30, 2025 (down from $1,039.4M); R&D $68.6M Q2 vs $93.7M YoY.
- CEO John Houston to retire; board searching for successor; remains Chair.
- ARV-102 Phase 1: >50% LRRK2 reduction in CSF, >90% in PBMCs; dosing in Parkinson's.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/0001655759-25-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/arvn-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer